CEO and Co-Founder, B.Sc. MBA.
Mr. Izraeli conceived the idea behind the Polyrizon technology during the final year of his studies at Ben Gurion University of the Negev. Izraeli was involved in chemical engineering development projects within the framework of the European Union Ammonore Project. He holds a B.Sc. degree in chemical engineering and MBA from Ben Gurion University of the Negev (BGU).
PhD, R&D Director
Dr Mike Yeadon, PhD. : Former VP/CSO of Pfizer’s Allergy & Respiratory group, he is an experienced R&D leader with training in biochemistry and pharmacology. He was responsible for the invention and clinical development of a sizeable A&R portfolio of new drugs and is a recognised expert in this field.
Dr. Yeadon is an Allergy & Respiratory Therapeutic Area expert, developed out of deep knowledge of biology & therapeutics and is an innovative drug discoverer with 24y in the pharmaceutical industry. He trained as a biochemist and pharmacologist. Joining Pfizer’s Allergy & Respiratory group in 1995, Dr Yeadon was responsible for target selection and the progress into humans of new molecules, leading teams of up to 200 staff across all disciplines and won an Achievement Award for productivity in 2008. Under his leadership the research unit invented oral and inhaled NCEs which delivered multiple positive clinical proofs of concept in asthma, allergic rhinitis and COPD. He led productive collaborations such as with Rigel Pharmaceuticals (SYK inhibitors) and was involved in the licensing of Spiriva® and acquisition of the Meridica (inhaler device) company, later acquired by Mylan. Dr Yeadon has published over 40 original research articles. Before leaving in 2011, Dr Yeadon was VP and Chief Scientific Officer (Allergy & Respiratory Research) with Pfizer.
Dr. Eyal S. Ron
Dr. Eyal S. Ron has over 25 years of experience in the development of drugs, biomaterials and drug delivery systems. He has a record of accomplishments for the creation of effective infrastructure for growth. Dr. Ron is effective in combining science with innovative business strategies, having developed and implemented the scientific, regulatory and clinical strategy for several companies. He has in-depth understanding of total development process including project management, clinical trials, regulatory, formulation, drug delivery, QC and manufacturing scale-up. He has contributed to the formation of Cerebrotec, Combinent Biomedical Systems, eNOS Pharmaceuticals, Focal, GelMed/Gel Sciences, Gelesis, InfiMed, Palmetto Pharmaceuticals, Pharmedica and Sensei Biomaterials.
Dr. Yana Khrapunsky
Project Manager, PhD.
Dr. Khrapunsky is a molecular biology scientist. She completed her B.Sc, M.Sc (Cum Laude) and a doctoral degree from Ben Gurion University. During her studies, she received prestigious academic awards like, the Levzion PhD fellowship (Israeli Ministry of Education) for outstanding PhD students from periphery, the Kreitman fellowship, the Knesset award of distinguished M.Sc students and the Rector award from the Ben Gurion University. Dr. Khrapunsky published several scientific articles and lectured in a few conferences.